Compare BDTX & WHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BDTX | WHF |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.3M | 162.2M |
| IPO Year | 2020 | 2012 |
| Metric | BDTX | WHF |
|---|---|---|
| Price | $2.57 | $7.23 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 6 | 2 |
| Target Price | ★ $10.60 | $7.75 |
| AVG Volume (30 Days) | ★ 1.7M | 210.8K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | ★ 24.83% |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.38 | ★ 0.42 |
| Revenue | $70,000,000.00 | ★ $76,339,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $6.72 | $16.95 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.20 | $6.39 |
| 52 Week High | $4.94 | $11.31 |
| Indicator | BDTX | WHF |
|---|---|---|
| Relative Strength Index (RSI) | 27.63 | 44.62 |
| Support Level | $2.61 | $7.13 |
| Resistance Level | $2.72 | $7.84 |
| Average True Range (ATR) | 0.25 | 0.19 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 18.30 | 10.51 |
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.